Hunan Fangsheng Pharm Co Ltd (603998) - Net Assets
Based on the latest financial reports, Hunan Fangsheng Pharm Co Ltd (603998) has net assets worth CN¥1.75 Billion CNY (≈ $256.40 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.03 Billion ≈ $443.60 Million USD) and total liabilities (CN¥1.28 Billion ≈ $187.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Hunan Fangsheng Pharm Co Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.75 Billion |
| % of Total Assets | 57.8% |
| Annual Growth Rate | 15.77% |
| 5-Year Change | 37.06% |
| 10-Year Change | 86.2% |
| Growth Volatility | 29.32 |
Hunan Fangsheng Pharm Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Hunan Fangsheng Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Hunan Fangsheng Pharm Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Hunan Fangsheng Pharm Co Ltd (2011–2024)
The table below shows the annual net assets of Hunan Fangsheng Pharm Co Ltd from 2011 to 2024. For live valuation and market cap data, see 603998 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.73 Billion ≈ $253.87 Million |
+9.20% |
| 2023-12-31 | CN¥1.59 Billion ≈ $232.48 Million |
+5.36% |
| 2022-12-31 | CN¥1.51 Billion ≈ $220.66 Million |
+15.67% |
| 2021-12-31 | CN¥1.30 Billion ≈ $190.76 Million |
+3.00% |
| 2020-12-31 | CN¥1.27 Billion ≈ $185.22 Million |
+5.26% |
| 2019-12-31 | CN¥1.20 Billion ≈ $175.95 Million |
+8.05% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.84 Million |
+7.26% |
| 2017-12-31 | CN¥1.04 Billion ≈ $151.83 Million |
+5.91% |
| 2016-12-31 | CN¥979.69 Million ≈ $143.36 Million |
+5.15% |
| 2015-12-31 | CN¥931.73 Million ≈ $136.34 Million |
+10.66% |
| 2014-12-31 | CN¥841.94 Million ≈ $123.20 Million |
+117.64% |
| 2013-12-31 | CN¥386.85 Million ≈ $56.61 Million |
+21.33% |
| 2012-12-31 | CN¥318.83 Million ≈ $46.66 Million |
+23.34% |
| 2011-12-31 | CN¥258.49 Million ≈ $37.83 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Fangsheng Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 872.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥837.41 Million | 51.60% |
| Common Stock | CN¥439.09 Million | 27.05% |
| Other Components | CN¥346.47 Million | 21.35% |
| Total Equity | CN¥1.62 Billion | 100.00% |
Hunan Fangsheng Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Hunan Fangsheng Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Amata Corporation Public Company Limited
BK:AMATA
|
$706.14 Million |
|
Zhejiang Feida Environmental Science & Technology Co Ltd
SHG:600526
|
$706.15 Million |
|
RTW Venture Fund Ltd
LSE:RTW
|
$706.17 Million |
|
Velocity Financial Llc
NYSE:VEL
|
$706.42 Million |
|
Shenzhen Rapoo Technology
SHE:002577
|
$706.05 Million |
|
Solid Power Inc
NASDAQ:SLDP
|
$705.85 Million |
|
Nextool Technology Co. Ltd. A
SHG:688419
|
$705.70 Million |
|
Enghouse Systems Ltd
TO:ENGH
|
$705.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Fangsheng Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,458,093,676 to 1,622,965,416, a change of 164,871,740 (11.3%).
- Net income of 255,216,208 contributed positively to equity growth.
- Dividend payments of 129,500,631 reduced retained earnings.
- Share repurchases of 1,530,622 reduced equity.
- Other factors increased equity by 40,686,785.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥255.22 Million | +15.73% |
| Dividends Paid | CN¥129.50 Million | -7.98% |
| Share Repurchases | CN¥1.53 Million | -0.09% |
| Other Changes | CN¥40.69 Million | +2.51% |
| Total Change | CN¥- | 11.31% |
Book Value vs Market Value Analysis
This analysis compares Hunan Fangsheng Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 15.01x to 2.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.73 | CN¥10.99 | x |
| 2012-12-31 | CN¥0.92 | CN¥10.99 | x |
| 2013-12-31 | CN¥1.12 | CN¥10.99 | x |
| 2014-12-31 | CN¥3.19 | CN¥10.99 | x |
| 2015-12-31 | CN¥2.05 | CN¥10.99 | x |
| 2016-12-31 | CN¥2.13 | CN¥10.99 | x |
| 2017-12-31 | CN¥2.31 | CN¥10.99 | x |
| 2018-12-31 | CN¥2.45 | CN¥10.99 | x |
| 2019-12-31 | CN¥2.57 | CN¥10.99 | x |
| 2020-12-31 | CN¥2.68 | CN¥10.99 | x |
| 2021-12-31 | CN¥2.79 | CN¥10.99 | x |
| 2022-12-31 | CN¥3.24 | CN¥10.99 | x |
| 2023-12-31 | CN¥3.28 | CN¥10.99 | x |
| 2024-12-31 | CN¥3.69 | CN¥10.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Fangsheng Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.73%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.36%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 2.01x
- Recent ROE (15.73%) is above the historical average (12.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 22.06% | 19.75% | 0.80x | 1.39x | CN¥28.36 Million |
| 2012 | 22.51% | 19.90% | 0.88x | 1.28x | CN¥36.74 Million |
| 2013 | 20.56% | 18.35% | 0.86x | 1.31x | CN¥37.72 Million |
| 2014 | 10.03% | 19.49% | 0.45x | 1.15x | CN¥208.24K |
| 2015 | 10.24% | 19.35% | 0.44x | 1.20x | CN¥2.13 Million |
| 2016 | 7.51% | 13.06% | 0.42x | 1.37x | CN¥-23.09 Million |
| 2017 | 6.06% | 8.28% | 0.52x | 1.39x | CN¥-38.78 Million |
| 2018 | 6.93% | 6.94% | 0.64x | 1.56x | CN¥-32.41 Million |
| 2019 | 7.00% | 7.21% | 0.55x | 1.77x | CN¥-33.78 Million |
| 2020 | 5.54% | 4.99% | 0.57x | 1.95x | CN¥-51.38 Million |
| 2021 | 5.86% | 4.47% | 0.58x | 2.26x | CN¥-49.56 Million |
| 2022 | 20.56% | 15.95% | 0.61x | 2.10x | CN¥146.84 Million |
| 2023 | 12.81% | 11.47% | 0.53x | 2.11x | CN¥41.01 Million |
| 2024 | 15.73% | 14.36% | 0.54x | 2.01x | CN¥92.92 Million |
Industry Comparison
This section compares Hunan Fangsheng Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,208,953,488
- Average return on equity (ROE) among peers: 9.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Fangsheng Pharm Co Ltd (603998) | CN¥1.75 Billion | 22.06% | 0.73x | $706.12 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $7.31 Billion | 1.28% | 4.15x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $591.07 Million | 1.62% | 0.52x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $727.05 Million | 11.51% | 0.20x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $275.56 Million | 21.50% | 1.16x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.15 Billion | 23.74% | 0.91x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $292.94 Million | 7.42% | 0.73x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.71 Billion | 7.43% | 1.93x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $26.34 Billion | 6.76% | 0.18x | $3.30 Billion |
About Hunan Fangsheng Pharm Co Ltd
Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infe… Read more